Paragraph

Notice regarding Issuance of Stock-Compensation-Type Stock Options (Stock Acquisition Rights)

Retrieved on: 
Wednesday, June 28, 2023
Exercise, Shareholder, Restructuring, Person, Paragraph, Corporate law, Mass meeting, Corporate accountability for human rights violations, Partial, Acquisition, Ordinance, Grant (law), Organization, Tokyo Stock Exchange, Holding company, Airline, Security (finance), Bank, Lease, Real estate

TOKYO, June 28, 2023 (GLOBE NEWSWIRE) -- Internet Initiative Japan Inc. (“IIJ”, the “Company”, TSE Prime: 3774) announced that IIJ’s Board of Directors today resolved that stock-compensation-type stock options (Stock Acquisition Rights) be issued to Directors (excluding Part-time and Outside Directors) and Executive Officers of IIJ, in accordance with the provisions of Articles 236 Paragraph 1, Article 238 Paragraph 1 and 2 and Article 240 Paragraph 1 of the Corporation Law of Japan, as follows.

Key Points: 
  • Any acquisition of stock acquisition rights by transfer shall be subject to the approval by resolution of the Board of Directors of the Company.
  • The Company shall deliver stock acquisition rights, the number of which shall equal the number of stock acquisition rights held by the holder of the Remaining Stock Acquisition Rights.
  • Accordingly, the issuance of the stock acquisition rights is not an issuance of shares with favorable terms.
  • (14) Persons to be allotted stock acquisition rights, number of persons, and number of stock acquisition rights to be allotted

Panitch Schwarze Partners Named Among 2023 IP Stars by Managing Intellectual Property

Retrieved on: 
Monday, June 12, 2023
Vaccine, Star, Intellectual property, Managing Intellectual Property, Paragraph, Dunston, PTAB, IP, Organization, Patent Trial and Appeal Board, Radiation, Fortune 500, Patent, Invention, Hirschhorn, News, Creative industries, Generic drug

PHILADELPHIA, Pa., June 12, 2023 /PRNewswire-PRWeb/ -- Panitch Schwarze Belisario & Nadel LLP is pleased to announce that Managing Intellectual Property has named intellectual property attorneys Erin M. Dunston and Philip L. Hirschhorn 2023 IP Stars.

Key Points: 
  • PHILADELPHIA, Pa., June 12, 2023 /PRNewswire-PRWeb/ -- Panitch Schwarze Belisario & Nadel LLP is pleased to announce that Managing Intellectual Property has named intellectual property attorneys Erin M. Dunston and Philip L. Hirschhorn 2023 IP Stars .
  • In addition, Managing Intellectual Property ranked Panitch Schwarze Belisario & Nadel LLP as Highly Recommended in Intellectual Property Practice for 2023.
  • Managing Intellectual Property is a leading source of news and analysis on intellectual property issues worldwide.
  • The IP Stars survey identifies leading intellectual property law firms and attorneys in various jurisdictions to provide deeper insight into the complex and vibrant IP legal arena worldwide.

Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Yet Another “First Cycle” FDA Approval for an Abbreviated New Drug Application (ANDA), Dexmedetomidine Hydrochloride Injection

Retrieved on: 
Friday, June 9, 2023
FDA, Hospitals, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Retail, Supply Chain Management, Paragraph, Multimedia, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Hospital, Sodium acetate, Acquisition, Patient, File, Dexmedetomidine, ANDA, Summer, Generic drug, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230609005336/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230609005336/en/
    Dexmedetomidine Hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.
  • Dexmedetomidine Hydrochloride Injection 4mcg/ml in 50mL and 100mL is currently on FDA’s Drug Shortages list.
  • This latest approval of Dexmedetomidine Hydrochloride Injection will help reduce the recent supply issues for the product experienced in the U.S.
  • This new milestone also marks the approval of our second Paragraph IV Filing and the 5th ANDA approval for the Alter Pharma Group.

Partial Disposal of Shares of Common Stock Held by Nippon Telegraph and Telephone Corporation (Largest Shareholder), Acquisition of Shares of Common Stock by KDDI Corporation, Acquisition of Treasury Stock, etc.

Retrieved on: 
Thursday, May 18, 2023
Transfer, KDDI, Treasury, Purchasing, Subsidiary, IIJ, Share repurchase, Telecommunications, TSE, Treasury stock, Policy, Paragraph, Business, Article, NTT Communications, Mutatis Mutandis (album), Cabinet, Financial instrument, Rochester Telephone Corporation, Nippon Telegraph and Telephone, Tokyo Stock Exchange, Companies Act, Capital, Transaction, Business alliance, NTT, Financial Instruments and Exchange Act, Security (finance)

TOKYO, May 18, 2023 (GLOBE NEWSWIRE) -- Internet Initiative Japan Inc. (“IIJ”, the “Company”, TSE Prime: 3774) hereby announces that a series of capital transactions are scheduled to be implemented for a portion of IIJ’s shares of common stock held by Nippon Telegraph and Telephone Corporation (“NTT”), which is the largest shareholder of IIJ, in accordance with the NTT’s policy of disposing of the shares held by it. IIJ also hereby announces changes in Other Affiliated Company and Major Shareholders (each, as defined in the Financial Instruments and Exchange Act or relevant Cabinet Office Order) of IIJ as well as certain other matters.

Key Points: 
  • As of today, NTT has entered into the share purchase agreement with KDDI Corporation (“KDDI”) to transfer 18,707,000 shares (shareholding percentage (Note): 10.00%) out of the shares of IIJ’s common stock held by NTT to KDDI through off-market transaction (the “Share Transfer”).
  • The Share Transfer falls under a secondary offering of IIJ’s common stock.
  • NTT has informed IIJ that NTT intends to tender 3,928,500 shares (shareholding percentage (Note): 2.10%) out of the shares of IIJ’s common stock held by NTT in the Acquisition of Treasury Stock.
  • NTT has informed IIJ that NTT intends to continue holding such shares for the time being.

Evoke Pharma Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Teva Pharmaceuticals, Intellectual property, Anecdote, Paragraph, Quality of life, Certification, Patient, Gastroparesis, Metoclopramide, Pharmaceutical industry, Video game

SOLANA BEACH, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2023, and recent corporate developments.

Key Points: 
  • Doubled patient enrollment since Q1 2022; 127% increase
    SOLANA BEACH, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2023, and recent corporate developments.
  • Prescription fills also continue to rise with an 11% increase over the previous quarter,” said David A. Gonyer, R.Ph., Evoke Pharma’s CEO.
  • For the first quarter of 2023, selling, general and administrative expenses were approximately $2.8 million compared to $2.4 million for the first quarter of 2022.
  • Total operating expenses for the first quarter of 2023 were approximately $3.0 million compared to $2.5 million for the same period in 2022.

EQS-News: Reply SpA: The Board of Directors approves the quarterly report dated 31 March 2023

Retrieved on: 
Monday, May 15, 2023
Insurance, Communication, EXM, MTA, Internet, STAR, Internet of things, Paragraph, Intelligence, EBIT, Digital Services Act, Cloud computing, EBITDA, ISIN, Artificial intelligence, AI, Cryptocurrency, Mobile phone, Reply

All economic and financial indicators grew:

Key Points: 
  • All economic and financial indicators grew:
    Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2023.
  • In the first quarter of 2023 the consolidated EBITDA was €81.0 million compared to €70.9 million in 2022, equal to 15.6% of the turnover.
  • EBIT, from January to March, was €65.6 million (€57.7 million in 2022), and is equal to 12.6% of the turnover.
  • The net financial position of the Group on 31 March 2023 is also positive by 190.7 million.

REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 2023

Retrieved on: 
Monday, May 15, 2023
Technology, Mobile, Wireless, Finance, Other Technology, Professional Services, Internet, Data Management, Other Professional Services, Artificial Intelligence, Insurance, Communication, EXM, MTA, STAR, Internet of things, Paragraph, Intelligence, EBIT, Digital Services Act, Cloud computing, EBITDA, ISIN, Artificial intelligence, AI, Cryptocurrency, Mobile phone, Reply

Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2023.

Key Points: 
  • Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2023.
  • In the first quarter of 2023 the consolidated EBITDA was €81.0 million compared to €70.9 million in 2022, equal to 15.6% of the turnover.
  • EBIT, from January to March, was €65.6 million (€57.7 million in 2022), and is equal to 12.6% of the turnover.
  • The net financial position of the Group on 31 March 2023 is also positive by 190.7 million.

Supremex Announces Record Q1 2023 Results

Retrieved on: 
Wednesday, May 10, 2023
Town, Income Tax Act 1967, Envelope, Eastern Time Zone, Conference call, Wind, Pointe-Claire, EBITDA, Acquisition, Corporation, Income Tax Act, Adjustment, Remuneration, Conference, Legislation, Retail, Video game, Cryptocurrency, Paragraph, Webcast, Packaging and labeling

“Supremex posted solid first-quarter results with recent acquisitions driving revenue growth, leading to a thirteenth consecutive period of year-over-year improvement in Adjusted EBITDA.

Key Points: 
  • “Supremex posted solid first-quarter results with recent acquisitions driving revenue growth, leading to a thirteenth consecutive period of year-over-year improvement in Adjusted EBITDA.
  • “For the balance of 2023, our focus remains on integrating recent acquisitions with a priority on capturing all sales and cost synergies.
  • On May 9, 2023, the Board of Directors declared a quarterly dividend of $0.035 per common share, payable on June 23, 2023, to the shareholders of record at the close of business on June 8, 2023.
  • May 10, 2023 - First Quarter Results Conference Call:
    A conference call to discuss the Company’s results for the first quarter ended March 31, 2023 will be held Wednesday, May 10, 2023 at 8:00 a.m. (Eastern Time).

EQS-News: Goldshore Resources: New resource estimate comes to 6 million ounces of gold!

Retrieved on: 
Tuesday, May 9, 2023
Techno-economic assessment, Security, Paragraph, Gold, Publication, Acquisition, Risk, News, Palladium, Security (finance), Cryptocurrency, Mining

Goldshore Resources: New resource estimate comes to 6 million ounces of gold!

Key Points: 
  • Goldshore Resources: New resource estimate comes to 6 million ounces of gold!
  • In the process, the resource (open pit and underground) of the Moss deposit increased from 4.17 million ounces of gold contained in 121.7 million tonnes of ore (November 2022) to now 5.42 million ounces averaging 1.03 g/t gold contained in 163.6 million tonnes of ore!
  • In addition, the tonnage of the higher-grade shear zone area increased by 63% compared to the November 2022 resource estimate, and the contained ounces increased by 68%.
  • As a result, this higher-grade portion of the resource alone now contains 3.35 million ounces of the yellow metal at an average of 1.84 g/t gold!

REPLY S.p.A.: Shareholders’ Meeting approves the 2022 Financial Statements

Retrieved on: 
Thursday, April 20, 2023
Software, Digital Marketing, Internet, Data Management, Communications, Technology, Apps, Applications, Mobile, Wireless, Insurance, Shareholder, MTA, Reply, STAR, Paragraph, Record, Financial statement, EBIT, Legislature, II, Vserv Digital Services, Cloud computing, Share repurchase, Acquisition, ISIN, AI, Remuneration, Cryptocurrency

The General Shareholders’ meeting of Reply S.p.A. [MTA, STAR: REY] today approved the Financial Statements for the financial year 2022, confirming the distribution of a gross dividend of €1.00 per share.

Key Points: 
  • The General Shareholders’ meeting of Reply S.p.A. [MTA, STAR: REY] today approved the Financial Statements for the financial year 2022, confirming the distribution of a gross dividend of €1.00 per share.
  • The Reply Group closed the 2022 financial year with a consolidated turnover of €1,891.1 million, recording a 27.5% increase compared to €1,483.8 million for the 2021 financial year.
  • Consolidated EBITDA was €340.3 million, up 29.5% compared to €262.8 million recorded for the 2021 financial year.
  • EBIT, from January to December, was €285.5 million, up 36.4% compared to €209.3 million for the 2021 financial year.